Pharming Group N.V. (PHAR) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed Pharming Group N.V. (PHAR) over the past year, gaining 5.3% versus a loss of 33.7%. Over five years, ZVRA leads with a +16.6% price change compared with +1.0% for PHAR. Pharming Group N.V. is the larger company by market cap ($692.9 million vs $676.4 million), about 1.0 times the size.
On valuation, Zevra Therapeutics trades at a lower forward P/E (10.6x vs 31.9x for Pharming Group N.V.).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHAR | ZVRA |
|---|---|---|
| Share price | $9.79 | $11.39 |
| Market cap | $692.92M | $676.38M |
| 1-day change | +2.73% | +3.55% |
| YTD return | -46.07% | +27.12% |
| 1-year return | -33.68% | +5.27% |
| 5-year return | +0.95% | +16.58% |
| P/E ratio (TTM) | 75.31 | 12.38 |
| Forward P/E | 31.89 | 10.58 |
| EPS (TTM) | $0.13 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.34 | $15.04 |
| 52-week low | $9.44 | $8.01 |
| Distance from 52-week high | -54.12% | -24.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +250.87% | +119.49% |
| Average volume | 22.84K | 1.11M |
| Shares outstanding | 70.78M | 59.38M |
| Employees | 407 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZVRA has outperformed PHAR by 38.9 percentage points over the past year.
- Pharming Group N.V. trades at a higher earnings multiple (75.3x vs 12.4x trailing P/E).
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
PHAR vs ZVRA FAQ
Which is bigger, Pharming Group N.V. or Zevra Therapeutics?
Pharming Group N.V. (PHAR) is larger, with a market capitalization of $692.92M compared with $676.38M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, PHAR or ZVRA?
ZVRA returned +5.27% over the past 12 months, compared with -33.68% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PHAR or ZVRA?
ZVRA has the lower trailing P/E at 12.4, versus 75.3 for PHAR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Pharming Group N.V. and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.